MRFF – 2021 Optimising the Clinical Use of Immunoglobulins Grant Opportunity (GO ID: 5279)

The objective of The Medical Research Future Fund (MRFF) – PPHRI – 2021 Optimising the Clinical Use of Immunoglobulins Grant Opportunity is to provide grants of financial assistance to support Australian medical research and medical innovation projects that: 

  • Stream 1: conduct a randomised trial to compare different regimens for a therapeutic immunoglobulin in immunoglobulin responders following haematological malignancy. Examples include, but are not limited to: 
    • comparison of immunoglobulin continuation versus immunoglobulin cessation 
    • comparison of immunoglobulin continuation versus reduced immunoglobulin exposure. 
  • Stream 2: conduct a randomised trial to compare different regimens for a therapeutic immunoglobulin in immunoglobulin responders whose acquired hypogammaglobulinaemia is not due to haematological malignancy. Examples include, but are not limited to: 
    • comparison of immunoglobulin continuation versus immunoglobulin cessation 
    • comparison of immunoglobulin continuation versus reduced immunoglobulin exposure dose intervals. 
  • Stream 3: conduct a randomised trial to compare different regimens for a therapeutic immunoglobulin (e.g. varied dosage, duration, route of administration) against each other and/or other therapeutic options (e.g. alternative or concurrent therapies) for myasthenia gravis or chronic inflammatory demyelinating polyneuropathy, to inform their most cost-effective use. 
  • Stream 4: build the evidence base to inform the cost-effective clinical use of immunoglobulin in Australia. Examples include, but are not limited to: o retrospective studies that use linked health data to compare health outcomes following immunoglobulin cessation across populations 
    • development of improved clinical definitions for the indications for immunoglobulin or of response to immunoglobulin 
    • development of strategies to support the judicious use of immunoglobulin therapy by clinicians. 


Trial designs must include assessment of health outcomes which are relevant to patients, for example episodes of infections or admissions to hospital. Trial designs that also assess the potential for predictive biomarkers are preferred.

This grant opportunity is being administered by NHMRC on behalf of the Australian Government Department of Health.

Further information on the Medical Research Future Fund (MRFF) is available from the Department of Health’s MRFF website.